Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Position Held by Vivo Capital LLC
Vivo Capital LLC held its stake in shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) during the second quarter, Holdings Channel reports. The firm owned 500,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Sunesis Pharmaceuticals comprises about 0.3% of Vivo Capital LLC’s portfolio, making the stock its 25th largest position. Vivo Capital LLC’s holdings in Sunesis Pharmaceuticals were worth $1,350,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. TFS Capital LLC acquired a new stake in shares of Sunesis Pharmaceuticals during the first quarter worth $158,000. Renaissance Technologies LLC boosted its stake in Sunesis Pharmaceuticals by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 110,581 shares of the biopharmaceutical company’s stock worth $400,000 after buying an additional 16,000 shares during the last quarter. Finally, Neuberger Berman Group LLC boosted its stake in Sunesis Pharmaceuticals by 16.6% in the first quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 50.46% of the company’s stock.
Sunesis Pharmaceuticals, Inc. (NASDAQ SNSS) opened at 2.32 on Friday. Sunesis Pharmaceuticals, Inc. has a 12 month low of $2.19 and a 12 month high of $6.30. The company’s 50-day moving average is $2.62 and its 200-day moving average is $3.42. The company’s market cap is $54.55 million.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.35. During the same quarter in the previous year, the company posted ($0.12) earnings per share. On average, equities research analysts expect that Sunesis Pharmaceuticals, Inc. will post ($1.61) EPS for the current fiscal year.
A number of equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 price target on shares of Sunesis Pharmaceuticals in a report on Thursday, July 27th.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Want to see what other hedge funds are holding SNSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.